A number of research firms have recently commented on Zeltiq Aesthetics Inc (NASDAQ:ZLTQ). Analysts at Leerink Swann initiated coverage on shares of ZELTIQ Aesthetics in a research note on Friday, February 21st. They set an “outperform” rating and a $26.00 price target on the stock. Separately, analysts at Maxim Group raised their price target on shares of ZELTIQ Aesthetics from $16.00 to $25.00 in a research note on Tuesday, January 21st. They now have a “buy” rating on the stock. Finally, analysts at Goldman Sachs downgraded shares of ZELTIQ Aesthetics from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 14th. They now have a $21.00 price target on the stock, up previously from $19.00. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $22.30. Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) stock opened at $19.13 in last session, and closed at $17.44, while the day range of ZLTQ stock is $17.06-$19.13.The stock showed a negative weekly performance of -14.00%.
Zacks upgraded shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) from an underperform rating to a neutral rating in a research note released on Thursday morning, American Banking News reports. They currently have $62.50 target price on the stock. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) stock opened at $56.85, in last session and closed at $53.74, by loosed -5.40%.The 52 week range was $32.90-$101.00.Company’s market capitalization is $1.57 billion.
Ventrus Biosciences Inc (NASDAQ:VTUS) On Feb. 12 announced top line efficacy and safety results from the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related to anal fissure (AF). In this randomized double blind trial comparing diltiazem 2% cream versus placebo cream in 434 subjects in 90 centers globally, both treatment arms demonstrated a clinically meaningful improvement. The diltiazem 2% treatment arm demonstrated no significant improvement compared to placebo in the primary endpoint of average of worst anal pain associated with or following defecation. The mean of worst AF-related pain score at baseline was 7.09 for diltiazem 2% and 7.18 for placebo, decreasing to 3.81 (-3.28 difference) and 3.72 (-3.46 difference) respectively. Ventrus Biosciences Inc (NASDAQ:VTUS) stock loosed -5.44% and finished the last session at $-5.44.The EPS of the stock remained -1.00.Company’s market capitalization is $28.99 million.
Gentiva Health Services (NASDAQ:GTIV) released its earnings data on Tuesday. The Gentiva Health Services (NASDAQ:GTIV) reported $0.14 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.30 by $0.16, American Banking & Market News reports. Gentiva Health Services, Inc. (NASDAQ:GTIV) stock opened the session at $9.63, and closed the session at $8.80.The 52 week range of the GTIV stock remained $8.47-$13.85 and the day range was $8.60-$9.65.
Leave a Reply